Citations 1
N0234: Phase II study of erlotinib (OSI-774) plus gemcitabine as first-or second-line therapy for metastatic breast cancer (MBC)
Graham, David L. , Hobday, Timothy J. , Rousey, Steven R., Nair, Sreekumar, Soori, Gamini S. , Sabagh, Tarek, Perez, Edith A. , Hillman, David W.
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 644-644
